

13 March 2026

## Release of Shares from Escrow

**Philadelphia PA and Phoenix AZ, 13 March 2026:** Commercial dermatology company, Botanix Pharmaceuticals Limited (ABN 70 009 109 755) (ASX:BOT, “Botanix” or “the Company”) announces, pursuant to ASX Listing Rule 3.10A, that 3,111,145 fully paid ordinary shares will be released from voluntary escrow on 20 March 2026.

Authorised for release by

**Vince Ippolito**

Executive Chairman

### About Botanix Pharmaceuticals

Botanix Pharmaceuticals Limited (ASX:BOT) is a dermatology company based in Philadelphia and Phoenix (US), which has received FDA approval for *Sofdra*, its product for the treatment of primary axillary hyperhidrosis. *Sofdra* is the first and only new chemical entity approved by FDA to treat primary axillary hyperhidrosis and presents a novel, safe and effective solution for patients who have lacked treatment options for this socially challenging medical condition.

To learn more please visit: <http://www.botanixpharma.com/>

### For more information, please contact:

**General enquiries**

Corporate Communications  
Botanix Pharmaceuticals  
P: +61 8 6285 0083  
[info@botanixpharma.com](mailto:info@botanixpharma.com)

**Investor enquiries**

Hannah Howlett  
P: +61 4 5064 8064  
[investors@botanixpharma.com](mailto:investors@botanixpharma.com)

**Media enquiries**

Haley Chartres  
H^CK  
P: +61 423 139 163  
[haley@hck.digital](mailto:haley@hck.digital)